mTOR和SGLT-2抑制剂:它们对年龄相关过程的协同作用
Dario Troise1,2, Silvia Mercuri1, Barbara Infante1
1Nephrology, Dialysis and Transplantation Unit, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
International journal of molecular sciences
|August 29, 2024
概括
准衰老细胞可以延长寿命并减少与年龄相关的疾病. 本综述探讨了结合mTOR和SGLT-2抑制剂对抗衰老的潜在协同效益.
科学领域:
- 老年学和细胞衰老研究.
- 衰老和慢性疾病的药理学.
- 代谢途径和细胞调节.
背景情况:
- 老龄化是慢性疾病的主要风险因素,导致全球死亡率和医疗保健负担显著.
- 衰老细胞随着年龄的增长而积累,并导致与年龄相关的疾病.
- 目前的研究重点是老年疗法,即消除老化的细胞的药物.
研究的目的:
- 审查mTOR和SGLT-2抑制剂在向细胞衰老方面的潜在协同作用.
- 探索这些药物类别如何在打击衰老过程中相互补充.
- 突出结合老化疗法未来研究的途径.
主要方法:
- 对mTOR抑制剂,SGLT-2抑制剂和细胞衰老研究的文献综述.
- 对每个药物类别的已知作用机制的分析.
- 探索潜在的相互作用和对衰老途径的协同效应.
主要成果:
- mTOR抑制剂调节细胞生长,新陈代谢和免疫力,影响衰老.
- SGLT-2 抑制剂通过调节葡萄糖再吸收来改善代谢健康.
- 证据表明,这些药物如何影响衰老的潜在重叠和协同作用.
结论:
- 结合mTOR和SGLT-2抑制剂可能是针对衰老的强大策略.
- 这种组合可以提高寿命,减少与年龄相关的疾病.
- 需要进一步的直接研究来验证这些联合疗法的协同效益.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Mitochondria
11.5K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
11.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Electron Transport Chain: Complex I and II
12.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.3K
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178


